Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies

Author(s): Lei Cao, Lei Fan, Wei Xu, Jian-Yong Li

Journal Name: Current Cancer Drug Targets

Volume 15 , Issue 9 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Mouse double minute 4 (MDM4) as a member of MDM family, is an oncogene emerging as an imperative negative regulator of p53. Tumor suppressor protein p53 plays a crucial role in cell cycle arrest, apoptosis and homeostasis. It has been reported that frequent inactivation of p53 was observed in numerous human cancers including hematologic malignancies. MDM4, the newly discovered modulator of p53 protein, is frequently amplified in various solid tumors such as cutaneous melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and mantle cell lymphoma. Multiple evidences implicate that over-expression of MDM4 is associated with tumor progression and poor prognosis which can be reversed by knockdown of MDM4 expression or restoration of p53 function, and support the rationale for the design of future MDM4-specific therapeutics. This article discusses and focuses on using MDM4 as a novel biomarker as well as a therapeutic target for hematologic malignancies.

Keywords: Biomarker, hematologic malignancies, MDM2, MDM4, p53, therapeutic approach.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [769 - 780]
Pages: 12
DOI: 10.2174/156800961509151110124616
Price: $65

Article Metrics

PDF: 44
PRC: 1